Welcome to our dedicated page for iSpecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen stock.
iSpecimen Inc., headquartered in Lexington, MA, is a leading marketplace for human biospecimens. The company provides researchers with the specimens they need from the patients they want through its innovative iSpecimen Marketplace. This online platform connects healthcare organizations with access to patients and specimens with scientists in need of these vital resources.
Utilizing proprietary, cloud-based technology, iSpecimen enables researchers to intuitively search for specimens across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. This system allows for easy and compliant access to specimens, facilitating scientific discovery and advancing healthcare for all.
iSpecimen stands out by offering a unique value proposition to both researchers and partner sites. Researchers gain the necessary resources to drive their studies, while partner sites can contribute to biomedical discovery and benefit financially. The company caters to a global market, with operations spanning the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority of its revenue coming from the Americas.
In recent news, iSpecimen has achieved a sequential quarterly revenue growth of 75%, driven by enhanced operational efficiencies and new business initiatives. The company continues to expand its network by adding new suppliers and reinforcing existing relationships to provide researchers with increased access to highly sought-after biospecimens, especially for oncology research. Additionally, iSpecimen is making strides in quality control and assurance through digital AI histopathology services, enhancing data quality and operational efficiency.
For investors and media inquiries, iSpecimen's contacts at KCSA Strategic Communications are available for further information.
iSpecimen Inc. (Nasdaq: ISPC) has partnered with Acutis Diagnostics to enhance its biospecimen marketplace platform, introducing custom sequencing services for cancer and COVID-19 samples. This collaboration aims to streamline the research process by providing a single source for samples and corresponding sequencing data, improving researchers' ability to study genetic mutations linked to these diseases. Given the high demand for biospecimens related to cancer and COVID-19, this initiative is set to foster advancements in medical diagnostics and therapeutics.
iSpecimen (Nasdaq: ISPC) has announced that CEO Christopher Ianelli will participate in the Maxim Group’s 2022 Virtual Growth Conference from March 28-30, 2022. The corporate presentation will be available on-demand starting March 28, 2022, at 9:00 a.m. ET for all registrants. iSpecimen connects scientists with healthcare providers through its online marketplace for biospecimens essential for medical research. For more details about the conference or one-on-one meetings, attendees can reach out to Maxim representatives or KCSA Strategic Communications.
iSpecimen Inc. (Nasdaq: ISPC) announced its marketplace network has exceeded 200 healthcare providers, significantly enhancing access to biospecimens for medical research. This platform connects researchers with healthcare organizations, improving procurement efficiency for crucial samples such as tissues and biofluids. The diverse supplier network ensures a reliable flow of specimens, addressing potential shortages from global disruptions. The company emphasizes compliance and rigorous vetting for its suppliers to maintain high ethical and operational standards.
iSpecimen Inc. (Nasdaq: ISPC) reported a record FY 2021 revenue of $11.1 million, a 36% increase from FY 2020's $8.2 million. The revenue consisted of $8.0 million (72%) from non-COVID-19 related sources and $3.1 million (28%) from COVID-19. The company expanded its supplier network to 200 organizations and customer purchases grew to 415. iSpecimen raised $21 million in a private placement, enhancing its capabilities for biospecimen research. However, net loss increased to $9.0 million from $4.7 million in 2020.
iSpecimen (NASDAQ: ISPC) announced CEO Dr. Christopher Ianelli's participation in the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Dr. Ianelli will present on February 24 at 12:30 p.m. ET. Interested attendees can add the event to their calendars via an iCalendar link. iSpecimen operates an online marketplace for human biospecimens, enabling life scientists to connect with healthcare providers for research needs. For further inquiries or one-on-one meetings, contact KCSA Strategic Communications.
iSpecimen Inc. (NASDAQ: ISPC) will release its fourth quarter and full year financial results for 2021 on February 17, 2022, before market opening. An audio webcast will follow at 8:30 a.m. ET, featuring key executives including CEO Christopher Ianelli. Investors can join the live call at +1-877-425-9470 (U.S.) or +1-201-389-0878 (International). A replay option will be available until March 3, 2022. iSpecimen offers a marketplace for human biospecimens, connecting researchers with healthcare providers.
iSpecimen (Nasdaq: ISPC) announced the addition of a reference lab in New York to enhance its supplier capabilities for COVID-19 research. This lab can sequence hundreds of COVID-19 positive swabs weekly, aiding in the identification of variants like Omicron and Delta. iSpecimen has provided over 15,000 specimens for more than 200 COVID-related projects since the pandemic's onset and has collaborated with the CDC by supplying positive and negative serum samples. This expansion supports researchers' needs for variant identification in the ongoing fight against COVID-19.
iSpecimen Inc. (Nasdaq: ISPC) announced participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Christopher Ianelli will present on-demand starting January 10 at 7:00 a.m. ET. iSpecimen provides an online marketplace connecting life scientists with healthcare providers for biospecimens.
For more details, contact H.C. Wainwright or KCSA Strategic Communications at iSpecimen@kcsa.com.
iSpecimen Inc. (NASDAQ: ISPC) announced a significant expansion of its global supplier network, with 25% of new suppliers located outside the U.S. This growth enhances the iSpecimen Marketplace, which now includes over 200 suppliers. The company aims to meet increasing demands for biospecimens in Europe and Asia-Pacific, supporting various medical research fields. Key benefits include improved access to biospecimens and addressing worldwide research needs. The iSpecimen Marketplace streamlines procurement for life science researchers, tackling the shortage of quality biospecimens.
iSpecimen (Nasdaq: ISPC) announced the expansion of its global biospecimen provider network to support research on neurological disorders, affecting approximately one billion people worldwide. Over the past ten months, it has added over a dozen sample providers, supplying biospecimens such as cerebrospinal fluid and other biofluids. iSpecimen can now provide samples from COVID-19 patients exhibiting neurological symptoms, assisting researchers facing biospecimen shortages. This initiative follows National Epilepsy and Alzheimer’s Awareness Months, aiming to facilitate medical discoveries related to these conditions.
FAQ
What is the current stock price of iSpecimen (ISPC)?
What is the market cap of iSpecimen (ISPC)?
What is iSpecimen Inc.?
Where is iSpecimen Inc. headquartered?
How does the iSpecimen Marketplace work?
What kind of specimens does iSpecimen provide?
What recent achievements has iSpecimen made?
Who can benefit from using iSpecimen's services?
What regions does iSpecimen operate in?
How can researchers access iSpecimen's services?
How does iSpecimen ensure quality control?
How can investors get in touch with iSpecimen?
